98%
921
2 minutes
20
Organophosphorus hydrolase (OPH), a promising biocatalyst for the degradation of organophosphorus compounds, faces application limitations due to its structural fragility. To address this, we developed a novel bioinorganic hybrid nanoflowers (HNFs) system by integrating OPH with copper phosphate via a self-assembly strategy. The HNFs exhibited significant catalytic robustness across a broad pH and temperature range. This hybrid system demonstrated enhanced tolerance to organic solvents and proteases, retaining 81% of its initial activity after five catalytic cycles. Furthermore, we successfully tandem-catalyzed the enzymatic hydrolysis and metal-catalyzed hydrogenation reactions using OPH and copper phosphate as the bio- and metal catalysts, respectively, thereby completely converting the toxic substrate into low-toxicity products. This bifunctional catalytic system offers a novel solution for the deep detoxification of organophosphorus pollutants.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/acs.jafc.5c03908 | DOI Listing |
Toxicol Mech Methods
September 2025
Department of Toxicology and Military Pharmacy, Military Faculty of Medicine, Hradec Kralove, University of Defence, Brno, Czech Republic.
The decontamination of chemical warfare agents or compounds involved in chemical industry incidents poses a significant challenge to environmental protection and human health. These compounds are highly toxic and could be relatively resistant to conventional decontamination methods. In recent years, surfactants have emerged as a promising option, as they can enhance the solubility of organophosphorus compounds in aqueous solutions while promoting their degradation or adsorption onto surfaces.
View Article and Find Full Text PDFPestic Biochem Physiol
November 2025
Research Base of Zhengzhou University, State Key Laboratory of Cotton Bio-breeding and Integrated Utilization, Institute of Cotton Research, Chinese Academy of Agricultural Sciences, Anyang 455000, Henan, China; State Key Laboratory of Cotton Bio-Breeding and Integrated Utilization, School of Agricu
Chlorpyrifos (CPF), a widely used organophosphate insecticide in cotton cultivation for controlling Aphis gossypii, has Binodoxys communis as the primary parasitic natural enemy of A. gossypii. This study evaluated the impact of two sub-lethal CPF concentrations (LC10 and LC30) on key biological parameters across two generations, transcriptomic responses, and symbiotic bacterial communities in B.
View Article and Find Full Text PDFAnal Methods
September 2025
College of Engineering, Jilin Normal University, Siping 136000, Jilin, China.
Glyphosate, a widely used organophosphorus herbicide in agriculture, poses potential threats to aquatic ecosystems and human health due to its long-term environmental persistence. This study presents a spectroscopic detection system based on a competitive reaction utilizing the Ponceau 4R (P4R)-Cu complex. Leveraging glyphosate's high affinity for chelating copper ions, the method enables indirect, rapid, and visual quantitative analysis of glyphosate.
View Article and Find Full Text PDFJ Toxicol Sci
August 2025
Department of Drug Metabolism and Molecular Toxicology, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences.
Ionic liquids (ILs) are salts with melting points below 100°C. These materials are promising novel solvents in organic reactions, as new electrolytes, and in protein stabilization, able to refold enzymes and aid in drug discovery. IL properties are strongly influenced by the types of their constituent cations and anions.
View Article and Find Full Text PDFJ Manag Care Spec Pharm
September 2025
Division of Medical Oncology, Department of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles.
Background: Alectinib, brigatinib, and lorlatinib are all preferred first-line (1L) therapies for anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in National Comprehensive Cancer Network (NCCN) guidelines. Although clinical trials have demonstrated their efficacy, real-world evidence on treatment patterns, costs, and outcomes may help differentiate these therapies and inform optimal 1L treatment selection in the absence of head-to-head comparisons.
Objective: To evaluate real-world outcomes for patients with ALK+ NSCLC receiving 1L ALK tyrosine kinase inhibitors (TKIs), focusing on drug acquisition costs, health care utilization, and clinical outcomes.